Pacira Pharmaceuticals, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
Pacira Pharmaceuticals, Inc. to Present at the 24thAnnual Piper Jaffray Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)-- Pacira Pharmaceuticals, Inc. (NAS: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at the 24th Annual Piper Jaffray Healthcare Conference at The New York Palace Hotel on Tuesday, November 27, at 2 p.m. ET. Mr. Stack is expected to present an overview of the company.
A live audio webcast of the Pacira presentation can be accessed by visiting the "Investors & Media" section of the company's website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
Pacira Pharmaceuticals, Inc. (NAS: PCRX) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, EXPAREL® (bupivacaine liposome injectable suspension), was commercially launched in the United States in April 2012. EXPAREL and two other products have utilized the Pacira proprietary product delivery technology DepoFoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time. Additional information about Pacira is available at http://www.pacira.com.
Pacira Pharmaceuticals, Inc.
James S. Scibetta, 973-254-3570
Chief Financial Officer
KEYWORDS: United States North America New Jersey New York
The article Pacira Pharmaceuticals, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.